Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top-line but beat on the bottom-line: revenue of $7.67M was 8.14% below the $8.35M expected, primarily due to a significant decrease in system sales volume. However, gross margin expanded to 58.49% (vs. 58.28% expected) due to favorable product mix, and EPS GAAP of -$0.05 beat the consensus of -$0.06. The quarter was marked by the strategic acquisition of Robocath and regulatory clearances for the Synchrony and MAGiC products, despite ongoing pressure from the Johnson & Johnson catheter transition.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Stereotaxis(STXS) the Revenue is 7.67 M (-12.82%), Miss estimate;the EBIT is -4.568 M (-14.86%), Beat estimate;the EPS is -0.05 (+0%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B12.82%
0.01B5.09%
-0.00B7.73%
EBITExceed expectations
-0.00B14.86%
-0.00B22.58%
+0.00B7.72%
EPSExceed expectations
-0.05--
-0.056713.34%
+0.006713.34%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf